FDA 483 - Teligent Pharma, Inc.

An FDA inspection of Teligent, Inc. in Buena, NJ, revealed significant deficiencies in their in-vitro bioequivalence studies. The firm failed to properly retain reserve samples, maintain adequate drug accountability records, and ensure the scientific validity of their analytical methods. These issues indicate a lack of control over critical aspects of their BE study conduct and data integrity.